Ondo Finance and Alpaca Collaborate to Tokenize US Stocks and ETFs

3.9.2025 16:30:00 EEST | Business Wire | Press release

Today, Ondo Finance, a leader in blockchain-based financial innovation and tokenized real-world assets, announced the launch of Ondo Global Markets, their platform for tokenized US stocks and ETFs. The platform is powered by a strategic integration with Alpaca, a self-clearing broker-dealer and brokerage infrastructure API for stocks, ETFs, and options trading, as well as crypto.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903244835/en/

Ondo Finance and Alpaca collaborate to tokenize US stocks and ETFs; bridging traditional finance and on-chain markets, increasing access to high-quality assets.

According to a McKinsey report, the tokenized market capitalization could reach around $2 trillion by 2030 across a variety of asset classes. This expected rise in market demand for tokenized assets, like US stocks and ETFs, comes as global investors continue to face barriers, including strict market access rules, high minimums, and cumbersome settlement processes. The collaboration between Ondo and Alpaca aims to remove these barriers.

100+ Assets Live, 1,000+ Coming – Leading tokenized stocks and ETFs are now available, with plans to scale to 1,000+ by year-end
Transferable 24/7 – Tokenized stocks and ETFs are transferable peer-to-peer and available 24/7/365 where allowed
Deep Liquidity – Global Markets provides access similar to traditional exchange liquidity for on-chain investors
Usable in DeFi – Ondo assets behave like stablecoins for ease of use and automation, enabling tokenized stocks to be used in DeFi
Industry Backing – Ondo tokenized stocks are fully backed by US stocks and ETFs which are held in custody by US broker-dealers and independent security agents

Available now across qualified Asia-Pacific, African, and Latin American markets, Ondo Global Markets is providing access to over 100 tokenized US stocks and ETFs, with plans to increase to over 1,000 assets available by the end of the year.

“Global investors have historically faced barriers to accessing the approximately $63 trillion US securities markets due to high fees, limited access, transfer frictions, platform fragmentation, and geographic exclusions, locking millions out of capital markets,” says Ian De Bode, Chief Strategy Officer at Ondo Finance. “Working with Alpaca allows us to tokenize US stocks and ETFs with the speed, accessibility, and programmability of blockchain for these global investors.”

"The future of finance lies in bridging traditional and decentralized markets," says Yoshi Yokokawa, CEO and Co-Founder of Alpaca. "Ondo reflects that, and Alpaca is dedicated to enabling this transformation globally with the infrastructure that makes it possible."

This collaboration highlights the ongoing evolution of the financial landscape, where technology may make certain investment opportunities more globally accessible. Ondo Global Markets is currently available on Ethereum, with Solana and BNB Chain launching soon.

About Alpaca

Alpaca is a US-headquartered self-clearing broker-dealer and brokerage infrastructure for stocks, ETFs, fixed income, 24/5, options trading, and offers crypto–raising over USD170 million in funding. Alpaca is backed by top-tier investors globally, including Portage Ventures, Spark Capital, Tribe Capital, Social Leverage, Horizons Ventures, Unbound, SBI Group, Derayah Financial, Elefund, and Y Combinator. For more information, visit: alpaca.markets

About Ondo Finance

Ondo is a blockchain technology company. Its mission is to accelerate the transition to an open economy by building the platforms, assets, and infrastructure that bring financial markets on-chain. For more information, visit ondo.finance

Please read Characteristics and Risks of Standardized Options before investing in options.

All investments involve risk; for more information, please see our Disclosure Library. Cryptocurrency is highly speculative, volatile, and may result in total loss of value. Please click here for more information.

Tokenization services are not available in all jurisdictions. Alpaca Crypto LLC provides digital asset services, while securities underlying tokenized assets are custodied by Alpaca Securities LLC. Neither entity is the issuer of, or involved in, the tokenization of any assets. Tokenized assets are issued by third parties, do not represent direct equity ownership, and carry unique risks. Please review the Tokenization Disclosure for risk information.

Alpaca Securities LLC (member FINRA/SIPC) and Alpaca Crypto LLC (NMLS# 2160858 a FinCEN-registered MSB, not a member of FINRA/SIPC) are wholly owned subsidiaries of AlpacaDB, Inc.; cryptocurrencies carry unique risks and are not FDIC- or SIPC-protected. This is not an offer or solicitation to buy or sell securities or cryptocurrencies, or to open an account, in any jurisdiction where Alpaca is unregistered or unlicensed.

Alpaca and Ondo Finance are not affiliated; neither party is responsible for the liabilities of the other.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250903244835/en/

Contacts

Media Contact
press@alpaca.markets

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 15:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.

Fortegra Completes Acquisition by DB Insurance29.5.2026 23:30:00 EEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom